Published in Women's Health Weekly, June 23rd, 2011
Lybrel® had total U.S. sales of just under $12 million for the twelve months ending April 30, 2011, according to IMS Health. Lybrel® tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.